|
| Press Releases |
|
 |
|
| Friday, March 26, 2021 |
|
|
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021 |
| Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel, the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ. more info >> |
|
| Tuesday, March 23, 2021 |
|
|
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan |
| Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma. more info >> |
|
| Monday, March 22, 2021 |
|
|
Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan |
| Eisai Co., Ltd. announced today that, as part of one strategic investment towards the realization of its medium-term business plan "EWAY2025", it has conducted the groundbreaking ceremony for the construction of a new injection/research building "Eisai Medicine Innovation Technology Solutions" ("EMITS") at the Kawashima Industrial Park located in Gifu Prefecture, Japan. more info >> |
|
|
Eisai Awarded The New Diversity Management Selection 100 |
| Eisai Co., Ltd. announced today that it was selected as one of winners of the Ministry of Economy, Trade and Industry (METI) Minister's Award of the New Diversity Management Selection 100 by METI. This marks the first time to be awarded ever since Eisai was included in the New Diversity Management Selection 100 Program. more info >> |
|
| Wednesday, March 17, 2021 |
|
|
DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders |
| Deutsches Zentrum fur Neurodegenerative Erkrankungen and Eisai Co., Ltd. today announced that both parties have entered into a research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders including Alzheimer's disease (AD) which modulate immune competence in neurons and glia cells. more info >> |
|
| Tuesday, March 16, 2021 |
|
|
Eisai: Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimer's Disease by Dian-Tu |
| Eisai Co., Ltd. announced today that anti-microtubule binding region (MTBR) tau antibody E2814, which was created from collaboration research between Eisai and University College London, has been selected by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU). more info >> |
|
| Friday, March 12, 2021 |
|
|
Eisai: Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anti-Cancer Agent Lenvima (Lenvatinib) With Prospective Indication for Uterine Body Cancer |
| Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Friday, March 5, 2021 |
|
|
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 15th International Conference on Alzheimer's and Parkinson's Disease |
| Eisai Co., Ltd. announced today that the latest data from its Alzheimer's disease (AD) and dementia pipeline, including the investigational anti-amyloid beta protofibril antibody lecanemab, will be presented at the 15th International Conference on Alzheimer's and Parkinson's Disease (AD/PD2021) to be held virtually from March 9 to 14, 2021. more info >> |
|
| Thursday, March 4, 2021 |
|
|
Eisai to Support Construction of Screening Framework for the Novel Coronavirus Infection in Kenya |
| Eisai Co., Ltd. announced today that it has decided to assent to and support a project led by CA Medlynks Kenya, Ltd., a subsidiary of the healthcare startup company engaged in improving healthcare access in Africa, Connect Afya Co., Ltd., which aims to build a new structure for the efficient testing framework for the novel coronavirus infection in Kenya. more info >> |
|
| Tuesday, March 2, 2021 |
|
|
New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong |
| Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Sharp Wins IAM's "Asia IP Elite 2025", Awarded to Companies with Outstanding Intellectual Property Strategy for The Second Consecutive Year
Nov 28, 2025 18:36 JST
|
|
|
Think Business, Think Hong Kong strengthens Italy-Hong Kong ties and opens new path for Asian collaboration
Nov 28, 2025 17:03 HKT/SGT
|
|
|
Fujitsu builds platform for NSK to create environmental value throughout the product lifecycle of bearing products
Nov 28, 2025 18:01 JST
|
|
|
Fujitsu launches Japan Edition of SAP Fioneer Cloud for Insurance, a next-generation platform supporting core business operations in the Japanese insurance industry
Nov 28, 2025 17:28 JST
|
|
|
Edvantage Group Announces FY2025 Annual Results
Nov 28, 2025 13:00 HKT/SGT
|
|
|
Magnolia Welcomes Tech Pioneer Luc Haldimann as New Board Chairman to Expand Global Growth and AI Strategy
Nov 28, 2025 00:00 HKT/SGT
|
|
|
NEC Launches Sales Support Solution Utilizing Agentic AI
Nov 27, 2025 22:31 JST
|
|
|
Fujitsu and Yamaguchi University develop low-power edge computing technology for near real-time image processing on small satellites
Nov 27, 2025 22:00 JST
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2025/26 Interim Results
Nov 27, 2025 18:43 HKT/SGT
|
|
|
PLN Collaborates with Norwegian and Japanese Stakeholders to Advance High-Integrity Cross-Border Carbon Markets at COP30 
Nov 27, 2025 18:30 HKT/SGT
|
|
|
Geespace Accelerates Global Expansion as GEESATCOM Enters New Markets
Nov 27, 2025 15:30 HKT/SGT
|
|
|
KEF, the premium speaker brand of Gold Peak, partners with Huawei to unlock new wireless high-fidelity experience with HUAWEI HiPlay
Nov 27, 2025 13:29 HKT/SGT
|
|
|
World's first ever spiral escalator renewal project conducted at a commercial facility in Mexico
Nov 27, 2025 11:00 JST
|
|
|
CBL International Limited Wins Prestigious 'CGMA Excellent Sustainability Award' at the CGMA Annual Awards 2025
Nov 26, 2025 18:54 HKT/SGT
|
|
|
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Nov 26, 2025 19:42 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
